2014年在76net必赢官网生物治疗国家重点实验室获博士学位，随后在76net必赢官网华西医院从事博士后研究，2015-2019年南加州大学访问学者。作为课题负责人承担国家自然科学基金委面上项目、青年科学基金，四川省自然科学基金青年基金项目，教育部-博士后基金等项目；参与国家重大科学研究计划（973计划）、国家重点研发计划、国家自然科学基金重大项目及重点项目等。以第一作者或通讯作者（含共同）在Signal Transduct Target Ther、Autophagy、Small、J Hematol Oncol、J Adv Res、Theranostics、Cancer Lett、Front Cell Dev Biol、Carcinogenesis等国际学术期刊发表20余篇学术论文，被包括Cell、Nat Metab、Nat Rev Drug Discov、Nat Rev Rheumatol、Nat Rev Microbiol、Nat Rev Mol Cell Biol、Trends Immunol、Trends Pharmacol Sci、Hepatology、Gut、Blood等在内的国际学术期刊引用2500余次，其中4篇入选ESI高被引论文。获教育部自然科学奖一等奖（第九完成人），入选第十四批四川省学术和技术带头人后备人选，担任Malignancy Spectrum杂志编委。中国药理学会分析药理学专业委员会、四川省国际医学交流促进会高原医学（区域联合）专委会委员。

讲授的课程

1. 科研素养与创新能力培养

2. 开放式医学创新讲坛

谢娜，副研究员，主要从事病毒诱导肿瘤发生发展过程中的相互作用网络、氧化应激、代谢调控和细胞自噬等机理及干预策略研究，以第一作者或通讯作者（含共同）在Signal Transduct Target Ther、Autophagy、Small、J Hematol Oncol、J Adv Res、Theranostics、Cancer Lett等国际学术期刊发表20余篇学术论文，其中4篇入选ESI高被引论文。

代表性论文

1. Xie N*, Shen G*, Gao W, Huang Z, Huang C#, Fu L#. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.

2. Li L, Tian H, Zhang Z, Ding N, He K, Lu S, Liu R, Wu P, Wang Y, He B, Luo M, Peng P, Yang M, Nice EC, Huang C, Xie N#, Wang D#, Gao W#. Carrier-Free Nanoplatform via Evoking Pyroptosis and Immune Response against Breast Cancer. ACS Appl Mater Interfaces. 2023;15(1):452-68.

3. Chen X, Feng L, Huang Y, Wu Y, Xie N#. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. Cancers. 2023; 15(1):104.

4. Lu S, Tian H, Li L, Li B, Yang M, Zhou L, Jiang H, Li Q, Wang W, Nice EC, Xie N#, Huang C#, Liu L#. Nanoengineering a Zeolitic Imidazolate Framework-8 Capable of Manipulating Energy Metabolism against Cancer Chemo-Phototherapy Resistance. Small. 2022: e2204926.

5. Duan J, Huang Z, Nice EC, Xie N#, Chen M#, Huang C#. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res. 2022:S2090-1232(22) 00188-6.

6. Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J, Nice EC, Xie N#, Huang C#, Shen Z#. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.

7. Zhang Y, Li J, Gao W#, Xie N#. Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges. Front. Biosci. (Landmark Ed). 2022;27(10):293.

8. Wu P, Han J, Gong Y, Liu C, Yu H#, Xie N#. Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. Pharmaceutics. 2022;14(10):1990.

9. An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B#, Xie N#. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett. 2021; 521:210-23.

10. Huang Z*, Xie N*, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, Tang Y. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021; 6(1): 162. (ESI高被引论文)

11. Wu P*, Gao W*, Su M, Nice EC, Zhang W, Lin J#, Xie N#. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021; 9: 357. (ESI高被引论文)

12. Xie N*, Zhang L*, Gao W*, Huang C, Huber PE, Zhou X, Li C#, Shen G#, Zou B#. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5(1):227. (ESI高被引论文)

13. Peng L, Jiang J, Tang B, Nice EC, Zhang YY#, Xie N#. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. Theranostics. 2020; 10(23):10360-77.

14. Zhang Z*, Zhou L*, Xie N*, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113. (ESI高被引论文)

15. Xie N*, Yuan K*, Zhou L, Wang K, Chen HN, Lei Y, Lan J, Pu Q, Gao W, Zhang L, Shen G, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H, Yang J, Huang C. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy. 2016; 12(9): 1507-20.